Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H23N3O2 |
| Molecular Weight | 349.4262 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCN1C(=O)\C(=N/NC(=O)C2=CC=CC=C2)C3=C1C=CC=C3
InChI
InChIKey=ZGQHMZCITJHYOW-QOCHGBHMSA-N
InChI=1S/C21H23N3O2/c1-2-3-4-10-15-24-18-14-9-8-13-17(18)19(21(24)26)22-23-20(25)16-11-6-5-7-12-16/h5-9,11-14H,2-4,10,15H2,1H3,(H,23,25)/b22-19-
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P21554|||Q5UB37 Gene ID: 1268.0 Gene Symbol: CNR1 Target Organism: Homo sapiens (Human) |
162.0 nM [Ki] | ||
Target ID: P34972 Gene ID: 1269.0 Gene Symbol: CNR2 Target Organism: Homo sapiens (Human) |
43.0 nM [Ki] | ||
Target ID: P20272 Gene ID: 25248.0 Gene Symbol: Cnr1 Target Organism: Rattus norvegicus (Rat) |
1.13 µM [Ki] | ||
Target ID: Q9QZN9 Gene ID: 57302.0 Gene Symbol: Cnr2 Target Organism: Rattus norvegicus (Rat) |
16.0 nM [Ki] |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-MDA-19
Created by
admin on Sat Dec 16 10:37:33 GMT 2023 , Edited by admin on Sat Dec 16 10:37:33 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MDA-19
Created by
admin on Sat Dec 16 10:37:33 GMT 2023 , Edited by admin on Sat Dec 16 10:37:33 GMT 2023
|
PRIMARY | MDA-19 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but failed to produce cannabis-like behavioural effects. | ||
|
X83OI5CX2U
Created by
admin on Sat Dec 16 10:37:33 GMT 2023 , Edited by admin on Sat Dec 16 10:37:33 GMT 2023
|
PRIMARY | |||
|
135743701
Created by
admin on Sat Dec 16 10:37:33 GMT 2023 , Edited by admin on Sat Dec 16 10:37:33 GMT 2023
|
PRIMARY | |||
|
MDA-19
Created by
admin on Sat Dec 16 10:37:33 GMT 2023 , Edited by admin on Sat Dec 16 10:37:33 GMT 2023
|
PRIMARY | CB2 receptor agonist. Displays 4-fold higher affinity for the human CB2 receptor than the human CB1 receptor (Ki values are 43.3 and 162.4 nM respectively) shows 70-fold affinity for the rat CB2 receptor over the rat CB1 receptor (Ki values are 16.3 and 1130 nM respectively). Attenuates tactile allodynia in a rat model does not affect rat locomotor activity. | ||
|
1104302-26-2
Created by
admin on Sat Dec 16 10:37:33 GMT 2023 , Edited by admin on Sat Dec 16 10:37:33 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
1048973-47-2
Created by
admin on Sat Dec 16 10:37:33 GMT 2023 , Edited by admin on Sat Dec 16 10:37:33 GMT 2023
|
PRIMARY | |||
|
DTXSID201029871
Created by
admin on Sat Dec 16 10:37:33 GMT 2023 , Edited by admin on Sat Dec 16 10:37:33 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
